<DOC>
	<DOCNO>NCT01685983</DOCNO>
	<brief_summary>The purpose study assess safety efficacy Korea Taiwan oral abiraterone acetate oral prednisolone men metastatic-castration resistant prostate cancer ( mCRPC ) disease progression follow treatment docetaxel-containing chemotherapy .</brief_summary>
	<brief_title>A Study Abiraterone Acetate ( JNJ-212082 ) Prednisolone Patients With Advanced Prostate Cancer</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , multicenter , single arm ( one treatment group ) study evaluate efficacy safety abiraterone acetate patient mCRPC . The study divide screen phase ( 28 day enrollment ) , treatment phase include treatment cycle ( cycle treatment 28 day ) , follow-up phase . Approximately 80 patient enrol study . Safety evaluation adverse event , clinical laboratory test , electrocardiogram vital sign well pharmacokinetic ( body drug ) assessment conduct study . Patients continue receive abiraterone acetate plus prednisolone disease progression occurrence unacceptable toxicity .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate ( stage IV ) Has document Prostate Specific Antigen ( PSA ) progression accord protocolspecific prostate specific antigen work group ( PSAWG ) eligibility criterion Has undergone prior chemotherapy prostate cancer regimen ( ) contain Docetaxel Has ongoing androgen deprivation serum testosterone le 50 ng/dL Has receive radiotherapy , chemotherapy , immunotherapy least 30 day prior treatment Eastern Cooperative Oncology Group Performance Status less equal 2 Active uncontrolled autoimmune disease may require corticosteroid therapy Serious uncontrolled coexistent nonmalignant disease , include active uncontrolled infection Uncontrolled hypertension Hemoglobin le equal 9.0 g/dL independent transfusion Has abnormal liver function test Surgery local prostatic intervention within 30 day first dose</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Metastatic-castration resistant prostate cancer</keyword>
	<keyword>Prostate specific antigen</keyword>
	<keyword>Abiraterone acetate</keyword>
	<keyword>JNJ-212082</keyword>
	<keyword>Abiraterone</keyword>
	<keyword>Prednisolone</keyword>
	<keyword>Androgen Deprivation</keyword>
	<keyword>Docetaxel-based chemotherapy</keyword>
</DOC>